GlaxoSmithKline (Ireland) Ltd.

The primary objective was to describe the long-term safety and tolerability of belimumab treatment in subjects with SSc-ILD by measuring the incidence of adverse events (AEs), adverse events of special interest (AESIs), and serious adverse events (SAEs). The secondary objective was to describe the long-term effect of belimumab on lung function in subjects with SSc-ILD by measuring the absolute change from baseline in forced vital capacity (FVC).

Primary objective (safety): To describe the long-term safety profile of GSK3511294 100 mg (SC, once every 26 weeks) added to existing asthma treatment in subjects with eosinophilic severe asthma during the 12-month open-label extension period. Secondary objective (efficacy): To evaluate the effects of long-term administration of GSK3511294 100 mg (SC, once every 26 weeks) added to existing asthma treatment during the 12-month open-label extension period on a range of clinical markers of asthma control and additional efficacy assessments. Other objectives: 1. To describe the long-term safety profile of GSK3511294 100 mg (SC, once every 26 weeks) added to existing asthma treatment in subjects with eosinophilic severe asthma during the 12-month open-label extension period. 2. To evaluate the effects of long-term administration of GSK3511294 on the patients' asthma severity scale. Pharmacodynamic (PD) objective: To evaluate the long-term PD effects of GSK3511294. Healthcare resource utilization endpoint Objective: To further evaluate the effect of GSK3511294 100 mg SC on healthcare resource utilization.

Primary objectives: 1. To evaluate the efficacy of depemokimab compared with placebo at week 52 in subjects diagnosed with CRSwNP Secondary objectives: 1. To evaluate the efficacy of depemokimab compared with placebo at week 52 based on symptom scores of rhinorrhoea (runny nose) and anosmia 2. Based on Lund Mackay CT score, to evaluate the efficacy of the depemokimab group compared with the placebo group at week 52 3. To evaluate the effect of the depemokimab group on quality of life compared with the placebo group at week 52 in subjects diagnosed with CRSwNP 4. To evaluate the effect of the depemokimab group on asthma control compared with the placebo group at week 52 in the subgroup of asthma subjects diagnosed with CRSwNP 5. To evaluate the efficacy of the depemokimab group compared with the placebo group before week 26 in subjects diagnosed with CRSwNP 6. To evaluate the effect of the depemokimab group compared with the placebo group on nasal surgery at week 52 in patients diagnosed with CRSwNP 7. To evaluate the effect of the depemokimab group compared with the placebo group on the use of systemic glucocorticoids until week 52 in patients diagnosed with CRSwNP